Table of Content - Prostate Cancer Therapeutics Market Expected to Grow at 7.3% by 2032

Prostate Cancer Therapeutics Market By Therapy (Hormone Therapy, Luteinizing Hormone-releasing Hormone Analogs, Luteinizing Hormone-releasing Hormone Antagonists, Antiandrogens, Chemotherapy, Systemic Chemotherapy, Regional Chemotherapy, Biologic Therapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales, Others) - Growth, Share, Opportunities & Competitive Analysis, 2024 - 2032

06 Aug 2024 Format

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Prostate Cancer Therapeutics Market
2.2. Global Prostate Cancer Therapeutics Market, By Therapy, 2023 (US$ Million)
2.3. Global Prostate Cancer Therapeutics Market, By Distribution Channel, 2023 (US$ Million)
2.4. Global Prostate Cancer Therapeutics Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Prostate Cancer Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Prostate Cancer Therapeutics Market Vendors
3.2. Strategies Adopted by Prostate Cancer Therapeutics Market Vendors
3.3. Key Industry Strategies
4. Prostate Cancer Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Prostate Cancer Therapeutics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Hormone Therapy
5.3.2. Luteinizing Hormone-releasing Hormone Analogs
5.3.3. Luteinizing Hormone-releasing Hormone Antagonists
5.3.4. Antiandrogens
5.3.5. Chemotherapy
5.3.6. Systemic Chemotherapy
5.3.7. Regional Chemotherapy
5.3.8. Biologic Therapy
5.3.9. Targeted Therapy

6. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Sales
6.3.4. Others

7. North America Prostate Cancer Therapeutics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
7.3. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.Prostate Cancer Therapeutics Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
7.4.1.1.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
7.4.1.2.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
7.4.1.3.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

8. UK and European Union Prostate Cancer Therapeutics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.3. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.Prostate Cancer Therapeutics Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.1.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.2.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.3.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.4.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.5.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
8.4.1.6.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

9. Asia Pacific Prostate Cancer Therapeutics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.3. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.Prostate Cancer Therapeutics Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.1.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.2.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.3.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.4.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.5.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
9.4.1.6.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

10. Latin America Prostate Cancer Therapeutics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
10.3. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.Prostate Cancer Therapeutics Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
10.4.1.1.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
10.4.1.2.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
10.4.1.3.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

11. Middle East and Africa Prostate Cancer Therapeutics Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
11.3. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.Prostate Cancer Therapeutics Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
11.4.1.1.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
11.4.1.2.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Prostate Cancer Therapeutics Market: By Therapy, 2022-2032, USD (Million)
11.4.1.3.2. Prostate Cancer Therapeutics Market: By Distribution Channel, 2022-2032, USD (Million)

12. Company Profile
12.1. Astellas Pharma Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. AstraZeneca Plc
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Bayer AG
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. AbbVie
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Dendreon Pharmaceuticals LLC.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Exelixis, Inc
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Ferring B.V.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. GlaxoSmithKline Plc
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Ipsen Pharma
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Johnson & Johnson
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Novartis AG
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Pfizer Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Sanofi S.A
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives
12.14. Sumitomo Pharma America, Inc.
12.14.1. Company Overview
12.14.2. Financial Performance
12.14.3. Product Portfolio
12.14.4. Strategic Initiatives
12.15. Takeda Pharmaceutical Company Limited
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Product Portfolio
12.15.4. Strategic Initiatives
12.16. Tolmar Inc.
12.16.1. Company Overview
12.16.2. Financial Performance
12.16.3. Product Portfolio
12.16.4. Strategic Initiatives
12.17. Other Notable Players
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Product Portfolio
12.17.4. Strategic Initiatives